Transgenic mouse models in angiogenesis and cardiovascular disease

Journal of Pathology

Volumn 190, Issue 3, 2000, Pages 387-405

  Carmeliet, Peter ^a,b   Collen, Désiré ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Angiogenesis; Cardiovascular; Endothelial cell; Matrix metalloproteinases; Plasminogen; Proteinases; Smooth muscle cell; VEGF

Indexed keywords

GENE PRODUCT; VASCULOTROPIN;

ANGIOGENESIS; ARTERY OCCLUSION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; GENE FUNCTION; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RUPTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

EID: 0034095038     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200002)190:3<387::AID-PATH595>3.0.CO;2-R     Document Type: Review

References (162)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
2. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-1598.
3. Hirschi KK, d'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996; 32: 687-698.
4. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237: 1-30.
5. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
6. Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 1995; 204: 228-239.
7. Tomanek RJ, Ratajska A, Kitten GT, Yue X, Sandra A. Vascular endothelial growth factor expression coincides with coronary vasculogenesis and angiogenesis [in process citation]. Dev Dyn 1999; 215: 54-61.
8. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
9. Dor Y, Keshet E. Ischemia-driven angiogenesis. Trends Cardiovasc Med 1997; 7: 289-294.
10. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single vascular endothelial growth factor allele. Nature 1996; 380: 435-439.
11. Ferrara N, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442.
12. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259-270.
13. Carmeliet P, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98: 147-157.
14. Heymans S, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Med 1999; 5: 1135-1142.
15. Clauss M, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-1545.
16. Melder RJ, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium [see comments]. Nature Med 1996; 2: 992-997.
17. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995; 121: 4309-4318.
18. Gerber HP, et al. VEGF is required for growth and survival in neonatal mice. Development 1999; 126: 1149-1159.
19. Ferrara N, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med 1998; 4: 336-340.
20. Gerber HP, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation [see comments]. Nature Med 1999; 5: 623-628.
21. Clauss M. Functions of the VEGF receptor-1 (FLT-1) in the vasculature. Trends Cardiovasc Med 1998; 8: 241-245.
22. Grosskreutz CL, Anand-Apte B, Terman B, Quinn TP, D'Amore PA. Vascular endothelial growth factor (VEGF) is a chemoattractant for vascular smooth muscle cells (SMC). Invest Ophthalmol Vis Sci 1996; 37: 5470-5475.
23. Takagi H, King GL, Aiello LP. Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 1996; 45: 1016-1023.
24. Hariawala MD, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996; 63: 77-82.
25. van der Zee R, et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95: 1030-1037.
26. Asahara T, et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 1996; 94: 3291-3302.
27. Losordo DW, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
28. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PIGF). Curr Top Microbiol Immunol 1999; 237: 31-40.
29. Landgren E, Schiller P, Cao Y, Claesson-Welsh L. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 1998; 16: 359-367.
30. DiSalvo J, et al. A Purification and characterization of a naturally occurring vascular endothelial growth factor: placenta growth factor heterodimer. J Biol Chem 1995; 270: 7717-7723.
31. Birkenhager R, et al. Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Biochem J 1996; 316: 703-707.
32. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-25654.
33. Sawano A, Takahashi T, Yamaguchi S, Aonumura M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996; 7: 213-221.
34. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PIGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 1993; 9: 259-268.
35. Ziche M, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997; 76: 517-531.
36. Cao Y, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor: endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996; 271: 3154-3162.
37. Cao Y, Linden P, Shima D, Browne F, Folkman J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 1996; 98: 2507-2511.
38. Oloffson B, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A 1996; 93: 2576-2581.
39. Taipale J, et al. Vascular endothelial growth factor receptor-3. Curr Top Microbiol Immunol 1999; 237: 85-96.
40. Dumont DJ, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282: 946-949.
41. Joukov V, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290-298.
42. Kukk E, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggest a role in lymphatic vascular development. Development 1996; 122: 3829-3837.
43. Kuipainen A, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995; 92: 3566-3570.
44. Lymboussaki A, et a. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol 1998; 153: 395-403.
45. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family [corrected; erratum to be published]. Proc Natl Acad Sci U S A 1996; 93: 11675-11680.
46. Avantaggiato V, Orlandini M, Acampora D, Oliviero S, Simeone A. Embryonic expression pattern of the murinc figf gene, a growth factor belonging to platelet-derived growth factor/vascular endothelial growth factor family. Mech Dev 1998; 73: 221-224.
47. Achen MG, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998; 95: 548-553.
48. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745.
49. Dumont DJ, et al. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 1995; 203: 80-92.
50. Yamaguchi TP, Dumont DJ, Conlon RA, Breitman ML, Rossant J. flk-1, an fit-related receptor tyrosine kinase, is an early marker for endothelial cell precursors. Development 1993; 118: 489-498.
51. Seetharam L, et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10: 135-147.
52. Gerber HP, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
53. Shalaby F, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66.
54. Shalaby F, Ho J, Stanford WL. et al. A requirement for Flk-1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997; 89: 981-990.
55. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725-732.
56. Eichmann A, et al. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci U S A 1997; 94: 5141-5146.
57. Witte L, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998; 17: 155-161.
58. Machein MR, Risau W, Plate KH. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 1999; 10: 1117-1128.
59. Khaliq A, et al. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors 1996; 13: 243-250.
60. Clark DE, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540-1548.
61. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
62. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 1998; 95: 9349-9354.
63. Kitsukawa T, et al. Ncuropilin semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 1997; 19: 995-1005.
64. Semenza GL, et al. Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest 1998; 114: 40S-45S.
65. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273: 6417-6423.
66. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP. The von Hippel Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997; 17: 5629-5639.
67. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon CM. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997; 386: 403-407.
68. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12: 149-162.
69. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17: 3005-3015.
70. Kozak KR, Abbott B, Hankinson O. ARNT-deficient mice and placental differentiation. Dev Biol 1997; 191: 247-306.
71. Gnarra JR, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 1997; 94: 9102-9107.
72. Carmeliet P, et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation, and tumor angiogenesis. Nature 1998; 394: 485-490.
73. Neufeld G, et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 1996; 15: 153-158.
74. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev 1997; 18: 4-25.
75. Poltorak Z, et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997; 272: 7151-7158.
76. Keyt BA, et al. The carboxyl-terminal domain (111 165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-7795.
77. Basic M, Edwards NA, Merrill MJ. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors 1995; 12: 11-15.
78. Carmeliet P, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nature Med 1999; 5: 495-502.
79. Vanoverschelde JLJ, et al. Circulation 1997; 95: 1961-1971.
80. Borgers M. Pathologic findings in chronic hibernating myocardium. In Stunning. Hibernation, and Preconditioning: Clinical Pathophysiology of Myocardial Ischemia, Heyndrickx GR, Vatner SF, Wijns W (eds). Lippincott-Raven: Philadelphia, 1997; 287-306.
81. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124.
82. Vassalli JD, Sappino JD, Belin D. The plasminogen activator/ plasmin system. J Clin Invest 1991; 88: 1067-1072.
83. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71-76.
84. Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovasc Med 1991; 1: 99-102.
85. Lawrence DA, Ginsburg D. Plasminogen activator inhibitors. In Molecular Biology of Thrombosis and Hemostasis, Roberts HR, High KA (eds). Marcel Dekker: New York, 1995; 517-543.
86. Vassalli JD. The urokinase receptor. Fibrinolysis 1994; 8: 172-181.
87. Blasi F, et al. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis 1994; 8: 182-188.
88. Saksela O, Rifkin D. Cell-associated plasminogen activation: regulation and physiological function. Annu Rev Cell Biol 1988; 4: 93-126.
89. Chapman HA, Jr, Stone OL. Co-operation between plasmin and elastase in elastin degradation by intact murine macrophages. Biochem J 1984; 222: 721-728.
90. Carmeliet P, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nature Genet 1997; 17: 439-444.
91. Martin TJ, Allan EH, Fukumoto S. The plasminogen activator and inhibitor system in bone remodelling. Growth Regul 1993; 3: 209-214.
92. Murphy G. Matrix metalloproteinases and their inhibitors. Acta Orthop Scand 1995; 66 (Suppl 256): 55-60.
93. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1996; 77: 863-868.
94. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49: 117-137.
95. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143.
96. Bacharach E, Itin A, Keshet E. In vivi patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci U S A 1992; 89: 10686-10690.
97. Carmeliet P, et al. Urokinase-type but not tissue-type plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81: 829-839.
98. Fearns C, Samad F, Loskutoff DJ. Synthesis and localization of PAI-1 in the vessel wall. In Advances in vascular biology, van Hinsbergh VWM (ed.). Gordon and Breach: Camberwell, Victoria, Australia, 1996; 207-227.
99. Pepper MS, Sappino AP, Montesano R, Orci L, Vassalli J-D. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J Cell Physiol 1992; 153: 129-139.
100. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181: 902-906.
101. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824-831.
102. Carmeliet P, et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-2755.
103. Carmeliet P, et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
104. Dewerchin M, et al. Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 1996; 97: 870-878.
105. Carmeliet P, et al. Receptor-independent role of urokinase-type plasminogen activator in arterial wound healing and intima formation in mice. J Cell Biol 1998; 140: 233-245.
106. Ploplis VA, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585-2593.
107. Nothnick WB, Soloway P, Curry TE. Assessment of the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) during the preovulatory period in female mice lacking a functional TIMP-1 gene. Biol Reprod 1997; 56: 1181-1188.
108. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 1996; 93: 3942-3946.
109. Wilting J, Christ B. Embryonic angiogenesis: a review. Naturwissenschaften 1996; 83: 153-164.
110. Sabapathy KT, et al. Polyoma middle-T induced vascular tumor formation: the role of the plasminogen activator/plasmin system. J Cell Biol 1997; 137: 953-963.
111. O'Reilly MS, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
112. Holmgren L, O'Reilly MS, Folkman J. Dormancy of metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-153.
113. Pappot H, et al. Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe-Seyler 1995; 376: 259-267.
114. Bajou K, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med 1998; 4: 923-928.
115. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340: 77-84.
116. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714-724.
117. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86 (Suppl III): 47-52.
118. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia a review. J Vasc Surg 1991; 13: 885-891.
119. Schwartz SM, Reidy MA, O'Brien ER. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost 1995; 74: 541-551.
120. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994; 89: 2809-2815.
121. van Leeuwen RT. Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrinolysis 1996; 10: 59-74.
122. Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen system and coagulation system in mice. Semin Thromb Hemost 1996; 22: 525-542.
123. Newman KM, et al. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg 1994; 20: 814-820.
124. Galis ZS, Sukhova GK, Kranzhöfer R. Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995; 92: 402-406.
125. Galis ZS, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-189.
126. Halpert I, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A 1996; 93: 9748-9753.
127. Irizarry E, et al. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 1993; 54: 571-574.
128. Sakalihasan N, Delvenne P, Nusgens BV, Limet R, Lapiere CM. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 1996; 24: 127-133.
129. Carmeliet P, et al. A model for arterial neointima formation using perivascular electric injury in mice. Am J Pathol 1997; 150: 761-777.
130. Carmeliet P, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice [see comments]. Circulation 1997; 96: 3180-3191.
131. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997; 99: 200-208.
132. Herbert JM, Lamarche I, Carmeliet P. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J Biol Chem 1997; 272: 23585-23591.
133. Shi C, et al. Plasminogen is not required for neointima formation in a mouse model of vein graft stenosis. Circ Res 1999; 84: 883-890.
134. Shi C, Russell ME, Bianchi C, Newell JB, Haber E. Murine model of accelerated transplant arteriosclerosis. Circ Res 1994; 75: 199-207.
135. Ploplis V, French E, Carmeliet P, Collen D, Plow E. The plasminogen system and cell migration during an inflammatory response. Fibrinolysis 1996; 10: Abstr 55.
136. Moons L, et al. Reduced transplant arteriosclerosis in plasminogen-deficient mice. J Clin Invest 1998; 102: 1788-1797.
137. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 2844-2850.
138. Belkin M, Donaldson MC, Whittemore AD. Abdominal aortic aneurysms. Curr Opin Cardiol 1994; 9: 581-590.
139. Ernst CB. Abdominal aortic aneurysm. N Engl J Med 1993; 328: 1167-1172.
140. Halloran BG, Baxter BT. Pathogenesis of aneurysms. Semin Vasc Surg 1995; 8: 85-92.
141. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-438.
142. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis 1994; 8: 253-262.
143. Schneiderman J, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89: 6998-7002.
144. Hamsten A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
145. Schneiderman J, et al. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J Clin Invest 1995; 96: 639-645.
146. Lupu F, et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-1455.
147. Plump AS, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
148. Xiao Q, et al. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A 1997; 94: 10335-10340.
149. Chapman HA, Jr, Stone OL, Vavrin Z. Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation. J Clin Invest 1984; 73: 806-815.
150. Reddy SG, Roberts WC. Frequency of rupture of the left ventricular free wall or ventricular septum among necropsy cases of fatal acute myocardial infarction since introduction of coronary care units. Am J Cardiol 1989; 63: 906-911.
151. Varbella F, et al. Subacute left ventricular free-wall rupture in early course of acute myocardial infarction. Clinical report of two cases and review of the literature. G Ital Cardiol 1999; 29: 163-170.
152. Dalrymple-Hay MJ, Monro JL, Livesey SA, Lamb RK. Postinfarction ventricular septal rupture: the Wessex experience. Semin Thorac Cardiovasc Surg 1998; 10: 111-116.
153. Zahger D, et al. Left ventricular free wall rupture as the presenting manifestation of acute myocardial infarction in diabetic patients. Am J Cardiol 1996; 78: 681-682.
154. Peuhkurinen K, Risteli L, Jounela A, Risteli J. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator. Am Heart J 1996; 131: 7-13.
155. Knoepfler PS, Bloor CM, Carroll SM. Urokinase plasminogen activator activity is increased in the myocardium during coronary artery occlusion. J Mol Cell Cardiol 1995; 27: 1317-1324.
156. Rohde LE, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99: 3063-3070.
157. Robert V, et al. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 1997; 76: 729-738.
158. Tyagi SC, Kumar S, Cassatt S, Parker JL. Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Can J Physiol Pharmacol 1996; 74: 983-995.
159. Zhang B, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794.
160. Lijnen HR, Collen D. Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding and thrombosis. Fibrinolysis 1989; 3: 67-77.
161. Henry M, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 1998; 18: 84-91.
162. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43: S42-S51.